TP53 and cancer: Hence, identifying drugs with high binding affinity for mutant p53 proteins, especially at nanomolar concentrations, would be highly desirable in attempts to improve current clinical chemotherapeutic regimens for many cancers, while overcoming non-specific toxicity.